CERUS CORP (CERS) Stock Price, Quote, News and Overview
NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD
CERS Quote, Performance and Key Statistics
CERUS CORP
NASDAQ:CERS (2/4/2025, 8:00:00 PM)
Premarket: 1.87 +0.01 (+0.54%)1.86
+0.06 (+3.33%)
The current stock price of CERS is 1.86 USD. In the past month the price increased by 10.71%. In the past year, price decreased by -21.19%.
CERS Latest News, Press Releases and Analysis
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update
Cerus Corporation to Participate in Upcoming Investor Conferences
Cerus Corporation Announces Third Quarter 2024 Financial Results
Cathie Wood's Ark Invest Buys $3.95M Worth Of Amazon Stock Amid Company's Nuclear Moves
Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting
CERS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 30.32 | 45.76B | ||
| COO | COOPER COS INC/THE | 25.76 | 19.02B | ||
| ALGN | ALIGN TECHNOLOGY INC | 23.04 | 16.03B | ||
| SOLV | SOLVENTUM CORP | 17.94 | 12.89B | ||
| LNTH | LANTHEUS HOLDINGS INC | 13.23 | 6.38B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 32.15 | 6.29B | ||
| BLCO | BAUSCH + LOMB CORP | 28.69 | 6.16B | ||
| ICUI | ICU MEDICAL INC | 28.34 | 3.94B | ||
| XRAY | DENTSPLY SIRONA INC | 10.43 | 3.83B | ||
| HAE | HAEMONETICS CORP/MASS | 16.89 | 3.46B | ||
| NEOG | NEOGEN CORP | 26.6 | 2.31B | ||
| UFPT | UFP TECHNOLOGIES INC | 39.91 | 2.15B |
Related stock screener links
About CERS
Company Profile
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 288 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Company Info
CERUS CORP
1220 Concord Avenue
Concord CALIFORNIA 94520 US
CEO: William M. Greenman
Employees: 631
Company Website: https://www.cerus.com/
Investor Relations: https://ir.cerus.com/
Phone: 19252886000
CERS FAQ
What is the stock price of CERS?
The current stock price of CERS is 1.86 USD.
What is the symbol for CERUS CORP stock?
The exchange symbol of CERUS CORP is CERS and it is listed on the Nasdaq exchange.
On which exchange is CERS stock listed?
CERS stock is listed on the Nasdaq exchange.
Is CERS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CERS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CERS.
Does CERS stock pay dividends?
CERS does not pay a dividend.
When does CERS stock report earnings?
CERS will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of CERS?
CERS does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.11).
What is the Short Interest ratio of CERS stock?
The outstanding short interest for CERS is 4.92% of its float.
CERS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CERS. When comparing the yearly performance of all stocks, CERS is a bad performer in the overall market: 76.27% of all stocks are doing better.
CERS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CERS. Both the profitability and financial health of CERS have multiple concerns.
CERS Financial Highlights
Over the last trailing twelve months CERS reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 57.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.41% | ||
| ROE | -36.88% | ||
| Debt/Equity | 1.21 |
CERS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CERS. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 40.05% and a revenue growth 11.12% for CERS